Coherus Oncology, Inc. (CHRS) Presents at UBS Virtual Oncology Day Transcript

Operator

Welcome to the UBS Virtual Event. David Dai, you may begin.

Xiaochuan Dai
UBS Investment Bank, Research Division

Great. Thank you, operator. Hi, everyone. I’m David Dai, I’m a biotech analyst here at UBS.

Thanks for joining our inaugural Virtual Oncology day today. We continue our session with Coherus. It’s our great pleasure to welcome Dennis Lanfear, Chief Executive Officer; Theresa Lavallee, Chief Development and Scientific Officer; and Rosh Dias, Chief Medical Officer. Thank you for joining us.

Theresa Lavallee
Chief Development Officer & Chairman of Scientific Advisory Board

Thanks for having us.

Dennis Lanfear
Chairman, President & CEO

Thank you for having us, David.

Xiaochuan Dai
UBS Investment Bank, Research Division

Excellent. So team, maybe to start things off, can you introduce yourself and provide a high-level overview of Coherus, including your pipeline as well as your strategy?

Dennis Lanfear
Chairman, President & CEO

Great. Well, thank you, David. First of all, let me thank you and UBS for having Coherus on today to talk about our company. Coherus Oncology is a company that is focused on enhancing the lives of cancer patients and delivering a step change in survival. We believe we have the right strategy to drive growth and to accomplish that. Our strategy really is in 3 distinct pieces that I’ll outline for you. The first is the drugs that we have on the market and the drugs that we are bringing to the market.

That includes LOQTORZI, our next-generation PD-1 as well